Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label safety extension study of tanezumab in cancer patients with pain due to bone metastases
2008-005182-66Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tanezumab in bone metastases, sponsored by Pfizer. Primary endpoints: Safety of tanezumab 10 mg IV and Efficacy of tanezumab 10 mg IV on bone metastasis pain. Started Jan 2009; status: completed.
02
Drugs
tanezumab
03
Conditions
bone metastases
Beyond the preview
Go deeper on 2008-005182-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005182-66.